VKTX Stock Recent News

Viking Therapeutics, Inc. stock has dropped ~35% amid market volatility, but Pfizer's withdrawal of danuglipron boosts VK2735's prospects as a leading oral GLP-1 for obesity. Goldman Sachs' Neutral rating highlights risks like high entry barriers, competition, and potential need for additional financing, impacting VK2735's commercial viability. Despite strong Phase II data, VK2735 faces competition from innovative obesity treatments, and strategic partnerships or buyouts could be crucial for Viking's success.

Investors are running into Viking Therapeutics (NASDAQ: VKTX) this week after an incident of drug-induced liver injury pushed Pfizer (NYSE: PFE) into terminating the development of its weight-loss pill.

13-week data from the Viking Therapeutics, Inc. phase 2 VENTURE-Oral Dosing trial using oral VK2735 for the treatment of patients with obesity, expected 2nd half of 2025. Pfizer's recent setbacks in weight-loss drugs may prompt it to consider acquiring VKTX, adding VK2735 and VK2809 to its pipeline. VK2735's dual administration routes and dual GLP-1/GIP agonist mechanism position it as a strong contender in the growing $37.94 billion anti-obesity market.

Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.

No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics (VKTX -1.14%), the turbulence has been extremely challenging thus far. The stock is down 71% over the past year, amid ongoing uncertainties regarding the timeline for future commercialization of its clinical pipeline and the broader stock market sell-off.

Bad news for Pfizer (PFE 1.07%) turned into good news for Eli Lilly (LLY 2.42%), Novo Nordisk (NVO 2.23%), and Viking Therapeutics (VKTX 8.48%) Monday morning, each of which is rising on Pfizer's latest product announcement.

Viking Therapeutics, Inc. VKTX,  Eli Lilly And Co LLY and Novo Nordisk A/S NVO stocks are trading higher on Monday.

When the stock market is as turbulent as it is these days, it's easy to forget the times when things are decidedly more cheery. However, sell-offs present great opportunities to buy stocks with significant upside potential.

Viking Therapeutics (VKTX 15.16%) is a healthcare company that possesses a lot of growth potential. And last year, its shares rose by 116%, as investors were bullish on its prospects.

One of the great things about equity markets is that you don't need a fortune to get started. Though strong companies that perform well tend to attract plenty of attention that bids up their share prices, it's possible to buy shares of quality stocks with $50 -- or less.